NASDAQ:OCUP • US67577R1023
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OCUPHIRE PHARMA INC (OCUP).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-10-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-20 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2024-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-31 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-17 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-26 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-24 | HC Wainwright & Co. | Initiate | Buy |
| 2021-04-05 | Alliance Global Partners | Initiate | Buy |
| 2021-03-29 | JonesTrading | Initiate | Buy |
| 2021-03-15 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-02-10 | Canaccord Genuity | Initiate | Buy |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 590K | 39.85M 6,654.24% | 19.049M -52.20% | 12.954M -32.00% | 15.238M 17.63% | 36.546M 139.83% | 218.39M 497.58% | 136.16M -37.65% | 156.17M 14.70% | 171.54M 9.84% | 187.36M 9.22% | |
| EBITDA YoY % growth | -22.7M -140.21% | 18.23M 180.31% | -8.557M -146.94% | -19.89M -132.44% | 8.874M 144.62% | 21.114M 137.93% | 123.03M 482.69% | 157.45M 27.98% | 188.32M 19.61% | 161.64M -14.17% | N/A | |
| EBIT YoY % growth | -22.7M -139.96% | 18.23M 180.31% | -8.563M -146.97% | -25.21M -194.41% | -3.756M 85.10% | 29.474M 884.63% | 149.7M 407.91% | 59.738M -60.09% | 76.063M 27.33% | 89.259M 17.35% | 102.84M 15.22% | |
| Operating Margin | -3,847.46% | 45.75% | -44.95% | -194.61% | -24.65% | 80.65% | 68.55% | 43.87% | 48.71% | 52.03% | 54.89% | |
| EPS YoY % growth | -1.59 74.68% | 0.76 147.80% | -0.48 -163.16% | -0.89 -85.94% | -0.92 -2.57% | -0.31 66.30% | 4.76 1,643.80% | 1.77 -62.74% | 2.18 22.99% | 2.47 13.08% | 2.75 11.57% |
All data in USD
| Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.26 -203.02% | 0.06 127.53% | -0.30 -2.00% | -0.28 8.20% | -0.26 0.99% | -0.19 -435.27% |
| Revenue Q2Q % growth | 2.152M -81.97% | 9.566M 465.70% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.925M -208.37% | 482.797K 109.41% | N/A | N/A | N/A | N/A |
All data in USD
9 analysts have analysed OCUP and the average price target is 17.09 USD. This implies a price increase of 1360.26% is expected in the next year compared to the current price of 1.17.
OCUPHIRE PHARMA INC (OCUP) will report earnings on 2024-11-08, before the market open.
The consensus EPS estimate for the next earnings of OCUPHIRE PHARMA INC (OCUP) is -0.26 USD and the consensus revenue estimate is 2.15M USD.
The consensus rating for OCUPHIRE PHARMA INC (OCUP) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.